NCT02928523View on ClinicalTrials.gov

PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

June 20, 2018

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

Autologous Fecal Microbiota Transplantation

Trial Locations (4)

13009

IPC, Marseille

44000

CHU Nantes, Nantes

69310

HCL Lyon Sud, Pierre-Bénite

75012

Hopital Saint Antoine, Paris

Sponsors

Lead Sponsor

MaaT Pharma
All Listed Sponsors
lead

MaaT Pharma

INDUSTRY

NCT02928523 - PreventiOn of DYSbioSis Complications With Autologous FMT in AML Patients | Biotech Hunter | Biotech Hunter